Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cationic amino acid transporter 1 (CAT-1), encoded by the SLC7A1 gene, is a high-affinity, low-capacity permease responsible for the sodium-independent transport of basic amino acids such as L-arginine, L-lysine, and L-histidine [1, 2]. Beyond its physiological role in maintaining cellular amino acid homeostasis and providing substrates for nitric oxide synthesis, CAT-1 serves as the primary cellular receptor for ecotropic murine leukemia viruses (MuLV) [3, 4]. Other related MuLV entry receptors include the phosphate transporters PiT-1 (SLC20A1) and PiT-2 (SLC20A2), which facilitate the entry of gibbon ape leukemia virus and amphotropic MuLV, respectively, as well as XPR1 for xenotropic and polytropic MuLV [4]. This dual functionality of CAT-1 makes it a critical component in both metabolic regulation and viral pathogenesis. In clinical contexts, CAT-1 is often exploited as a gateway for gene therapy vectors derived from MuLV, and its overexpression has been linked to increased proliferation in various cancers, including colorectal and breast malignancies [5]. Furthermore, its role in arginine transport is vital for endothelial function, where it supports the production of nitric oxide, a key regulator of vascular tone [1]. Consequently, CAT-1 and its related receptors represent significant targets for understanding viral entry mechanisms and developing strategies for metabolic or oncological interventions.
Facilitates the transport of cationic amino acids (arginine, lysine, histidine) across the plasma membrane via a sodium-independent, pH-insensitive mechanism (System y+). It also acts as a high-affinity receptor for the envelope glycoprotein of ecotropic murine leukemia viruses, mediating viral attachment and subsequent membrane fusion.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cationic amino acid transporter 1 (SLC7A1) (CAT-1).